About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 45628 record(s)
Req # A-2024-000610
Adverse Drug Reactions (ADRs) for C1 Esterase Inhibitor (Human). Report numbers: E2B_07240241, E2B_07202397, E2B_07203738, E2B_07211715, E2B_07200893, E2B_07212141, 001091444. ADR for Mesalimine. Report number: 001097077. ADR for VYVANSE. Report…Organization: Health Canada
February 2025
Req # A-2024-000613
Adverse Drug Reactions (ADRs) for GAMMAGARD LIQUID. Report numbers: 001092359, 001092364, 001090767, 001091341, 001090112, 001090121, 001090932, 001090109, 001090130. ADR for Prevacid. Report number: E2B_07222484.Organization: Health Canada
February 2025
Req # A-2024-000633
Adverse Drug Reactions (ADRs). Report numbers: 001090397, 001090829, 001095271, 001090911, E2B_07193408.Organization: Health Canada
February 2025
Req # A-2024-000702
Adverse Drug Reactions (ADRs). Report numbers: E2B_04932036, E2B_06747039.Organization: Health Canada
February 2025
Req # A-2024-000748
Adverse Drug Reactions (ADRs). Report numbers: E2B_06791238, E2B_07177078, 001026185, E2B_05649794, E2B_05046178.Organization: Health Canada
February 2025
Req # A-2024-000785
Adverse Drug Reactions (ADRs) for Ondansetron. Report numbers: E2B_07292216, E2B_07257754, E2B_07256411. ADRs for Pantoprazole sodium. Report numbers: E2B_07289678, E2B_07302776, E2B_07300609, E2B_07265897, E2B_07283554, 001099662. ADR for…Organization: Health Canada
February 2025
Req # A-2024-000826
Adverse Drug Reactions (ADRs). Report numbers: 001097163, E2B_07314826, 001095679.Organization: Health Canada
February 2025
Req # A-2024-000844
Adverse Drug Reactions (ADRs). Report numbers: E2B_06576446, E2B_07291807, E2B_07242295, E2B_07242732.Organization: Health Canada
February 2025
Req # A-2024-000905
Adverse Drug Reactions (ADRs). Report numbers: E2B_06729415, 001059606, E2B_06640045, E2B_06695186, E2B_06724909, 001060637.Organization: Health Canada
February 2025
Req # A-2024-000918
Adverse Drug Reactions (ADRs). Report numbers: E2B_07311444, E2B_06616049, E2B_07304055, 001092607, E2B_04857532, E2B_07285839, E2B 03541647, 001091444, 000947892, E2B_07309170.Organization: Health Canada
February 2025